 |
| |
| Apr-25-17 | Initiated |
Jefferies |
Buy |
|
|
| Mar-06-17 | Reiterated |
FBR & Co. |
Outperform |
$24 → $26 |
|
| Oct-06-16 | Resumed |
Brean Capital |
Buy |
$28 |
|
| May-27-16 | Initiated |
SunTrust |
Buy |
$18 |
|
| Dec-01-15 | Initiated |
FBR Capital |
Outperform |
$29 |
|
| Sep-09-15 | Initiated |
Raymond James |
Strong Buy |
|
|
| Aug-12-15 | Resumed |
H.C. Wainwright |
Buy |
$22 |
|
| Jun-19-15 | Reiterated |
Brean Capital |
Buy |
$22 → $28 |
|
| Dec-11-14 | Reiterated |
ROTH Capital |
Buy |
$25 → $33 |
|
| Dec-10-14 | Reiterated |
ROTH Capital |
Buy |
$25 → $33 |
|
| Oct-27-14 | Initiated |
H.C. Wainwright |
Buy |
$17 |
|
| Sep-25-14 | Reiterated |
Brean Capital |
Buy |
$19 → $22 |
|
| Jul-22-14 | Reiterated |
Brean Capital |
Buy |
$13 → $19 |
|
| Jul-02-14 | Reiterated |
MLV & Co |
Buy |
$10 → $16 |
|
| Apr-04-14 | Initiated |
Brean Capital |
Buy |
$13 |
|
| Mar-07-14 | Reiterated |
MLV & Co |
Buy |
$9 → $11 |
|
| Nov-25-13 | Reiterated |
Ladenburg Thalmann |
Buy |
$8 → $12 |
|
| Nov-06-13 | Initiated |
MLV & Co |
Buy |
$9 |
|
|
|
| Sep-15-17 07:30AM | TG Therapeutics, Inc. Announces the Phase 3 ULTIMATE Trials Evaluating TG-1101 in Patients with Multiple Sclerosis Are Now Open for Enrollment GlobeNewswire |
| Sep-13-17 11:01AM | Should You Buy TG Therapeutics Inc (TGTX) Now? Simply Wall St. |
| Sep-05-17 07:30AM | TG Therapeutics Announces Completion of Target Enrollment in the UNITY-CLL Phase 3 Trial GlobeNewswire |
| Sep-01-17 07:30AM | TG Therapeutics, Inc. Announces Clinical Data Presentations at the Upcoming 7th Joint ECTRIMS ACTRIMS Meeting GlobeNewswire |
| Aug-31-17 09:31PM | ETFs with exposure to TG Therapeutics, Inc. : September 1, 2017 Capital Cube |
| Aug-24-17 10:13AM | TG Therapeutics, Inc. :TGTX-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017 Capital Cube |
| Aug-14-17 08:28AM | TG Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : TGTX-US : August 14, 2017 Capital Cube |
| Aug-13-17 02:31AM | Edited Transcript of TGTX earnings conference call or presentation 9-Aug-17 12:30pm GMT Thomson Reuters StreetEvents |
| Aug-10-17 07:30AM | TG Therapeutics, Inc. Announces Successful Outcome from the First Pre-Planned Interim Analysis by Independent DSMB of the DLBCL Cohort in the UNITY-NHL Phase 2b Trial GlobeNewswire |
| Aug-09-17 01:01PM | TG Therapeutics reports 2Q loss Associated Press |
| 07:30AM | TG Therapeutics, Inc. Provides Business Update and Reports Second Quarter 2017 Financial Results GlobeNewswire |
| 05:50AM | Investor Network: TG Therapeutics, Inc. to Host Earnings Call ACCESSWIRE |
| Aug-07-17 05:04PM | What's Behind TG Therapeutics Inc.'s 14.4% Rally in July? Motley Fool |
| 07:30AM | TG Therapeutics, Inc. to Host Conference Call on Second Quarter 2017 Financial Results and Business Update GlobeNewswire |
| Aug-03-17 11:37PM | TG Therapeutics, Inc. Value Analysis (NASDAQ:TGTX) : August 4, 2017 Capital Cube -5.88% |
| Aug-02-17 09:13AM | TG Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : TGTX-US : August 2, 2017 Capital Cube |
| Aug-01-17 07:30AM | TG Therapeutics Announces Special Protocol Assessment (SPA) Agreement with the FDA for a Phase 3 Program of TG-1101 (ublituximab) for Patients with Multiple Sclerosis (MS) GlobeNewswire |
| Jul-25-17 01:35PM | ETFs with exposure to TG Therapeutics, Inc. : July 25, 2017 Capital Cube -5.81% |
| Jul-21-17 08:37AM | TG Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : TGTX-US : July 21, 2017 Capital Cube |
| Jul-14-17 05:08PM | ETFs with exposure to TG Therapeutics, Inc. : July 14, 2017 Capital Cube |
| Jun-28-17 09:02AM | TG Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : TGTX-US : June 28, 2017 Capital Cube |
| Jun-26-17 07:30AM | TG Therapeutics, Inc. Recaps Data from Triple Combination Therapy Trials at the 22nd European Hematology Association Annual Congress GlobeNewswire |
| 07:00AM | TG Therapeutics Recaps Preliminary Results from Ongoing Phase 2 Study of TG-1101 (ublituximab) in Patients with Multiple Sclerosis at the 3rd Congress of the European Academy of Neurology GlobeNewswire |
| Jun-21-17 06:48PM | Cramer's lightning round: This defeated stock is like flypaper CNBC |
| Jun-16-17 05:45AM | TG Therapeutics, Inc. Recaps Positive Data from the Phase 3 GENUINE Trial and Data from the Triple Combination of TG-1101, TGR-1202, and Ibrutinib at the 14th International Conference on Malignant Lymphoma GlobeNewswire |
| Jun-15-17 04:21PM | New Data Shows TG Therapeutics Could Be Onto Something Big Motley Fool |
| 03:27PM | ETFs with exposure to TG Therapeutics, Inc. : June 15, 2017 Capital Cube |
| 08:00AM | Biotech Industry Showing Signs of a Revival in 2017: Today's Research on BioCryst Pharmaceuticals and TG Therapeutics Accesswire |
| 04:00AM | TG Therapeutics, Inc. Announces Follow-Up Data from the Triple Combination of TG-1101, TGR-1202, and Bendamustine in Patients with DLBCL and FL at the 14th International Conference on Malignant Lymphoma GlobeNewswire |
| Jun-14-17 12:00PM | TG Therapeutics, Inc. Announces Follow-Up Data for Combination of TGR-1202 (umbralisib) plus Ibrutinib in Patients with Relapsed or Refractory CLL and MCL at the 14th International Conference on Malignant Lymphoma GlobeNewswire +5.16% |
| Jun-13-17 09:29AM | Excitement from ASCO: TG Thereapeutics, Loxo Oncology, and Bluebird Bio Motley Fool |
| 08:51AM | TG Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : TGTX-US : June 13, 2017 Capital Cube |
| 07:30AM | TG Therapeutics, Inc. Recaps Schedule of Clinical Data Presentations at the Upcoming 14th International Conference on Malignant Lymphoma & the 22nd European Hematology Association Annual Congress GlobeNewswire |
| Jun-08-17 07:30AM | TG Therapeutics, Inc. Announces Clinical Data Presentations at the Upcoming 14th International Conference on Malignant Lymphoma GlobeNewswire +5.69% |
| Jun-06-17 08:49AM | Are Options Traders Betting on a Big Move in TG Therapeutics (TGTX) Stock? Zacks |
| 07:30AM | TG Therapeutics, Inc. to Present at the 2017 Jefferies Global Healthcare Conference GlobeNewswire |
| Jun-05-17 02:50PM | ETFs with exposure to TG Therapeutics, Inc. : June 5, 2017 Capital Cube -6.14% |
| 10:56AM | U.S. stocks look for direction in shadow of U.K. terror attacks MarketWatch |
| 09:43AM | Stocks to Watch: Apple, Snap, Herbalife The Wall Street Journal |
| 09:37AM | UPDATE: TG Therapeutics stock rises 4% on positive late-stage cancer trial results MarketWatch |
| 09:00AM | TG Therapeutics, Inc. Announces Follow-Up Data from the Chemo-Free Triple Combination of TG-1101, TGR-1202, and Ibrutinib at the 53rd Annual Meeting of the American Society of Clinical Oncology GlobeNewswire |
| 08:00AM | Today's Research Reports on Stocks to Watch: Achillion Pharmaceuticals and TG Therapeutics Accesswire |
| Jun-03-17 06:00PM | TG Therapeutics Announces Positive Data from Phase 3 GENUINE Trial of TG-1101 in Combination with Ibrutinib in Patients with High Risk Chronic Lymphocytic Leukemia at the 53rd Annual Meeting of the American Society of Clinical Oncology GlobeNewswire |
| Jun-02-17 05:37PM | Why TG Therapeutics Inc Jumped Higher Today Motley Fool +17.37% |
| 07:30AM | TG Therapeutics, Inc. Recaps Schedule of Clinical Data Presentations at the Upcoming 53rd Annual Meeting of the American Society of Clinical Oncology GlobeNewswire |
| May-26-17 12:46PM | 5 Stocks Setting Up for Big Breakouts TheStreet.com |
| May-23-17 12:46PM | TG Therapeutics Stock Climbs After Successfully Completed Analysis in UNITY-CLL TheStreet.com |
| 07:30AM | TG Therapeutics, Inc. Announces Successful Outcome from Pre-Planned Interim Analysis by Independent DSMB in the UNITY-CLL Phase 3 Trial GlobeNewswire |
| May-22-17 08:17AM | TG Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : TGTX-US : May 22, 2017 Capital Cube |
| May-19-17 07:30AM | TG Therapeutics, Inc. Announces Clinical Data Presentations at the Upcoming 14th International Conference on Malignant Lymphoma GlobeNewswire |
| May-18-17 06:05AM | TG Therapeutics, Inc. Announces Clinical Data Presentations at the Upcoming 22nd European Hematology Association Annual Congress GlobeNewswire |
| May-17-17 05:05PM | TG Therapeutics, Inc. Recaps Clinical Data Presentations at the Upcoming 53rd Annual Meeting of the American Society of Clinical Oncology GlobeNewswire |
| May-15-17 04:44PM | ETFs with exposure to TG Therapeutics, Inc. : May 15, 2017 Capital Cube |
| May-12-17 10:55AM | TG Therapeutics, Inc. :TGTX-US: Earnings Analysis: Q1, 2017 By the Numbers : May 12, 2017 Capital Cube +6.33% |
| May-11-17 07:41PM | TG Therapeutics, Inc. Value Analysis (NASDAQ:TGTX) : May 11, 2017 Capital Cube |
| May-10-17 08:16AM | TG Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : TGTX-US : May 10, 2017 Capital Cube |
| May-05-17 08:22AM | 3 Intriguing Cancer Drugs With Data Coming at ASCO Next Month Motley Fool |
| 07:42AM | TG Therapeutics reports 1Q loss Associated Press |
| 07:30AM | TG Therapeutics, Inc. Provides Business Update and Reports First Quarter 2017 Financial Results GlobeNewswire |
| May-03-17 04:30PM | TG Therapeutics, Inc. to Host Conference Call on First Quarter 2017 Financial Results and Business Update GlobeNewswire |
| May-01-17 02:32PM | 3 Best Biotech Stocks During Trump's First 100 Days Motley Fool |
| Apr-28-17 08:30AM | TG Therapeutics Announces Preliminary Results from Ongoing Phase 2 Study of TG-1101 (ublituximab) in Patients with Multiple Sclerosis at the American Academy of Neurology 69th Annual Meeting GlobeNewswire -7.53% |
| Apr-26-17 03:38PM | ETFs with exposure to TG Therapeutics, Inc. : April 26, 2017 Capital Cube |
| 03:23PM | Harry Boxers two infrastructure stocks to watch MarketWatch |
| 07:30AM | Today's Research Reports on Stocks to Watch: Teva Pharmaceutical and TG Therapeutics Accesswire |
| Apr-25-17 06:59PM | Why TG Therapeutics Inc. Jumped Higher Today Motley Fool +15.38% |
| 11:40AM | Potential FDA Controversy Brewing For TG Therapeutics? Benzinga |
| Apr-24-17 07:30AM | TG Therapeutics, Inc. Recaps Schedule of Data Presentation at the Upcoming American Academy of Neurology 69th Annual Meeting GlobeNewswire |
| Apr-21-17 10:57AM | Physician Views Off-Label Use A 'Double-Edged Sword' For TG Therapeutics Benzinga |
| Apr-20-17 06:22PM | If You Don't Buy These 5 Stocks Before Their Looming Breakout, It's Your Loss TheStreet.com |
| 02:00PM | TG Therapeutics, Inc. Announces Clinical Data Presentations at the Upcoming 53rd Annual Meeting of the American Society of Clinical Oncology GlobeNewswire |
| Apr-18-17 07:30AM | FDA Drug Approvals on the Rise in 2017: Today's Research Reports on Sarepta Therapeutics and TG Therapeutics Accesswire |
| Apr-07-17 08:30AM | Is the Options Market Predicting a Spike in TG Therapeutics (TGTX) Stock? Zacks |
| Apr-04-17 01:22PM | TG Therapeutics stock rises 2% on preclinical data for cancer drug MarketWatch |
| 01:22PM | TG Therapeutics stock rises 2% on preclinical data for cancer drug |
| 01:00PM | TG Therapeutics, Inc. Announces Preclinical Data Presentation on the Companys Anti-PD-L1 Monoclonal Antibody at the American Association for Cancer Research Annual Meeting GlobeNewswire |
| 01:00PM | TG Therapeutics, Inc. Announces Preclinical Data Presentation on the Companys Anti-PD-L1 Monoclonal Antibody at the American Association for Cancer Research Annual Meeting |
| Apr-03-17 04:23PM | 3 Top Biotech Stocks to Buy in April Motley Fool -5.15% |
| 04:23PM | 3 Top Biotech Stocks to Buy in April at Motley Fool |
| Mar-30-17 10:33AM | 5 Top Performing Stocks of the Best ETF of Q1 Zacks |
| 10:33AM | 5 Top Performing Stocks of the Best ETF of Q1 |
| Mar-27-17 04:07PM | ETFs with exposure to TG Therapeutics, Inc. : March 27, 2017 Capital Cube |
| 04:07PM | ETFs with exposure to TG Therapeutics, Inc. : March 27, 2017 |
| Mar-22-17 01:04PM | TG THERAPEUTICS, INC. Financials -5.53% |
| 08:32AM | TG Therapeutics, Inc. :TGTX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 22, 2017 Capital Cube |
| 08:32AM | TG Therapeutics, Inc. :TGTX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 22, 2017 |
| Mar-20-17 07:30AM | TG Therapeutics, Inc. Announces Preclinical Data Presentation at the 2017 American Association for Cancer Research (AACR) Annual Meeting GlobeNewswire |
| Mar-19-17 01:51PM | Don't Let Offerings Blindside Your Thesis |
| Mar-17-17 07:30AM | TG Therapeutics, Inc. to Present at the 27th Annual Oppenheimer Healthcare Conference GlobeNewswire |
| Mar-16-17 09:30AM | TG Therapeutics and ImmunoGen are Models of Institutional Investor Attention Accesswire |
| 06:11AM | TG THERAPEUTICS, INC. Files SEC form 10-K, Annual Report |
| Mar-13-17 07:30AM | TG Therapeutics, Inc. to Present at the 29th Annual ROTH Conference GlobeNewswire +7.02% |
| Mar-10-17 07:54AM | TG Therapeutics reports 4Q loss |
| 07:37AM | Biotech Stock Mailbag: Puma's Rebound Explained, TG Therapeutics Approval Debate, Aurinia Next Steps |
| 07:34AM | TG THERAPEUTICS, INC. Files SEC form 8-K, Other Events |
| 07:30AM | TG Therapeutics, Inc. Announces Fourth Quarter and Year-End 2016 Financial Results and Business Update GlobeNewswire |
| 07:07AM | Q4 2016 TG Therapeutics Inc Earnings Release - After Market Close |
| Mar-09-17 05:06PM | TG THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Stateme +16.26% |
| 04:30PM | TG Therapeutics, Inc. to Host Conference Call on Fourth Quarter and Year-End 2016 Financial Results and Business Update GlobeNewswire |
| 09:19AM | TG Therapeutics, Inc. Announces Pricing of $50 Million Public Offering of Common Stock GlobeNewswire |
|
|
|
|
| TG Therapeutics, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases primarily in the United States. It develops TG-1101 (ublituximab), a chimeric, glycoengineered monoclonal antibody that targets an epitope on the CD20 antigen found on the surface of B-lymphocytes developed to aid in the depletion of circulating B-cells; and TG-1101 in combination with TGR-1202 for relapsed/refractory non-Hodgkin's lymphoma and chronic lymphocytic leukemia. The company also develops TGR-1202, an orally available phosphoinositide-3-kinase delta inhibitor with nanomolar potency to the delta isoform and high selectivity over the alpha, beta, and gamma isoforms, as well as for hematologic malignancies. In addition, it develops a pre-clinical program to develop interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors; bromodomain and extra terminal (BET) inhibitor program in the field of hematological malignancies; and anti-PD-L1 and anti-GITR antibody research programs that are in pre-clinical development stage in the field of hematological malignancies. The company has license agreements with LFB Biotechnologies S.A.S, GTC Biotherapeutics, LFB/GTC LLC, and Ildong Pharmaceutical Co. Ltd. for the development and commercialization of TG-1101 (ublituximab); Rhizen Pharmaceuticals, SA for the development and commercialization of TGR-1202; Ligand Pharmaceuticals Incorporated for the development and commercialization of IRAK4 inhibitor technology; Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs; and Jubilant Biosys for the development and commercialization of BET inhibitor program. TG Therapeutics, Inc. is headquartered in New York, New York. |
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Power Sean A | CFO, Secretary and Treasurer | Jun 19 | Sale | 11.04 | 30,000 | 331,200 | 447,464 | Jun 19 06:05 PM | | Power Sean A | CFO, Secretary and Treasurer | Jun 16 | Sale | 11.14 | 29,976 | 333,933 | 477,464 | Jun 19 06:05 PM | | KENNEDY WILLIAM JAMES | Director | Apr 11 | Sale | 10.27 | 8,548 | 87,788 | 70,401 | Apr 12 05:44 PM | | Charney Laurence N | Director | Apr 04 | Sale | 11.17 | 7,000 | 78,190 | 88,949 | Apr 04 05:57 PM | | Power Sean A | CFO, Secretary and Treasurer | Jan 04 | Sale | 4.55 | 8,816 | 40,113 | 507,440 | Jan 04 05:28 PM |
|
|
|
|
|
|
